A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Diseases and Conditions Researched

Bladder; Breast - Female; Lung; Pancreas; Stomach

What is the purpose of this trial?

To investigate the safety and efficacy of Nivolumab as a single agent or in combination with Ipilimumab in 4 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), and small cell lung cancer (SCLC).

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Bristol-Myers Squibb Company
Last Updated:
Study HIC#: 1311013060